title: [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].
abstract: BACKGROUND
  It is well known that central serous chorioretinopathy (CSCR) is triggered by endogenous and exogenous glucocorticoids but the exact pathomechanism is not completely understood. According to the results of previous studies overactivation of mineralocorticoid receptors may play a decisive role in the pathogenesis of CSCR.
  
  
  RESULTS
  Experimental studies have shown that overactivation of mineralocorticoid receptors in endothelial cells of the choroid induces increased permeability. In a pilot study inhibition of mineralocorticoid receptors was successful in treating CSCR. This article reports about the use of spironolactone in the treatment of CSCR. In this observational case series spectral-domain optical coherence tomographv (SD-OCT) showed either reduction or complete reabsorption of subretinal fluid. In pilot studies and in this case series inhibition of mineralocorticoid receptors as a therapeutic option was effective and safe; however, the efficacy is difficult to distinguish from spontaneous recovery, especially in acute CSCR.
  
  
  CONCLUSIONS
  For further assessment of this treatment controlled clinical trials are urgently required as this therapy would offer a new approach for patients with chronic CSCR and no tendency towards recovery.
authors: Augenklinik, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675, München, Deutschland, Mathias.Maier@mri.tum.de.
authors: M
authors: M
authors: Maier
authors: S
authors: S
authors: Stumpfe
authors: N
authors: N
authors: Feucht
authors: P
authors: P
authors: Strobl
authors: V
authors: V
authors: Rath
authors: C P
authors: CP
authors: Lohmann
mesh_terms: D000208:Acute Disease; D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000473:pathology*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D010865:Pilot Projects; D013148:Spironolactone / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone